Business
Seres Therapeutics Receives Award of Up to $3.6 Million from CARB-X to Develop Liquid Formulation of SER-155
Liquid formulation has potential to expand patient access, including those in intensive care, to SER-155 for the prevention of bloodstream and antimicrobial resistant (AMR) infectionsCAMBRIDGE, Mass., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator), a global non-profit partnership accelerating antibacterial products to address drug
About this update from Seres Therapeutics, Inc.
[{"type":"image","alt":"Seres Therapeutics, Inc.","displaySize":"","headline":null,"caption":"Seres Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":205,"height":85,"url":"https://media.zenfs.com/en/globenewswire.com/c9212fd90ce8aaab0f99113fa1623d37"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/k2NwaR5ktGr5v1rR6gsPpQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTM2MDtoPTE0OTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/c9212fd90ce8aaab0f99113fa1623d37","width":205,"height":85}},"lazy":false},{"type":"text","content":"Liquid formulation has potential to expand patient access, including those in intensive care, to SER-155 for the prevention of bloodstream and antimicrobial resistant (AMR) infections","length":183,"tagName":"p"},{"type":"text","content":"CAMBRIDGE, Mass., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator), a global non-profit partnership accelerating antibacterial products to address drug-resistant bacteria, a leading cause of death around the world, will provide up to $3.6 million in additional non-dilutive funding to the Company. The grant will support development and manufacturing of an oral liquid formulation of Seres’ Breakthrough Therapy designated SER-155, for medically vulnerable patient populations at risk of bloodstream infections (BSIs), including antimicrobial resistant infections, who cannot be dosed with oral capsules, such as intubated patients in the ICU.","length":809,"tagName":"p"},{"type":"text","content":"SER-155 is being developed for patients receiving allogeneic hematopoietic stem cell transplants (allo-HSCT), a population that is particularly susceptible to severe infections due to prolonged immunosuppression. In a randomized, placebo-controlled Phase 1b study evaluating SER-155 in this patient population, SER-155 reduced bacterial BSIs by 77% compared to placebo and significantly lowered systemic antibiotic use and febrile neutropenia. The Company recently received constructive FDA feedback on the design of a well-powered, placebo-controlled Phase 2 study and is finalizing the clinical protocol.","length":606,"tagName":"p"},{"type":"text","content":"“We have deeply appreciated CARB-X’s long-standing partnership wit...